Archives202520242023202220212020201920182017201620152014201320122011 March 30, 2020Subscription to raise £1.5 million to fund expansion of R&D pipeline Read More February 28, 2020Incanthera plc – Admission to trading on the NEX Exchange Growth Market Publication of Admission Document Read More February 17, 2020Oncology specialist Incanthera, in which ImmuPharma currently has a 14.0% shareholding, announces Rule 23 Notice in advance to quoting on NEX Exchange Growth Market Read More February 06, 2020ImmuPharma provides an update on the Avion Agreement in relation to Lupuzor’s™ new international Phase III trial Read More December 19, 2019Admission to trading on Euronext Growth Brussels Read More December 17, 2019Publication of Information Note – In advance to admission to trading on Euronext Growth Brussels Read More December 13, 2019Dual listing on Euronext growth Brussels Read More December 11, 2019Share price volatility Read More December 03, 2019ImmuPharma to present at Biotech Showcase™ 2020 in San Francisco Read More December 02, 2019TR1 – Notification of major interest in shareholdings Read More November 28, 2019ImmuPharma and Avion Pharmaceuticals sign exclusive licence Read More September 30, 2019INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2019 Read More 1…1011121314…16
February 28, 2020Incanthera plc – Admission to trading on the NEX Exchange Growth Market Publication of Admission Document Read More
February 17, 2020Oncology specialist Incanthera, in which ImmuPharma currently has a 14.0% shareholding, announces Rule 23 Notice in advance to quoting on NEX Exchange Growth Market Read More
February 06, 2020ImmuPharma provides an update on the Avion Agreement in relation to Lupuzor’s™ new international Phase III trial Read More
December 17, 2019Publication of Information Note – In advance to admission to trading on Euronext Growth Brussels Read More
